Roche's first-half sales hit by poor exchange rate and further Tamiflu decline
This article was originally published in Scrip
Roche's pharmaceutical sales for the first half of this year were down by 6% to CHF17.3 billion ($17 billion) when compared with the same period last year, but increased by 3% in local currencies. Roche Pharmaceuticals' sales were down by 4% at CHF11 billion andChugai, of which Roche owns 59.9%, had sales of CHF1.5 billion, down by 13%.
You may also be interested in...
Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.
A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.
Alcon's board of directors has finally approved a merger agreement with Novartis for the Alcon shares the latter does not already own, drawing a close to protracted negotiations that first began nearly a year ago.